TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16174897
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (EACA) 5 g infused during 1 hour, then 1 g/hour for 23 hours
Study: 11928795
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (external beam and brachytherapy)
Study: 9880769
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (not specified)
Study: 11928795
Drug: Adjuvant doxorubicin-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant doxorubicin-based chemotherapy
Study: 9788526
Drug: Alprazolam (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0, 1, 2 mg)
Study: 9788526
Drug: d‐amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine (0, 12.5, 25 mg)
Study: 9788526
Drug: Codeine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (0, 60, 120 mg)
Study: 9788526
Drug: Drug Recognition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Recognition Examiners (DREs) decisions
Study: 9788526
Drug: Drug class
Normalized name: VARIOUS DRUG CLASSES IN ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug class decisions by DREs
Study: 7697134
Drug: DMSA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSA (10 mg/kg, oral)
Study: 7697134
Drug: EDTA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA (1 g, intravenous)
Study: 2487304
Drug: Oral nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nitrofurantoin (100 mg t.i.d.) for five days
Study: 2487304
Drug: Oral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ampicillin (500 mg t.i.d.) for five days
Study: 20124
Drug: Beta1-adrenoceptor selective
Normalized name: beta-Arbutin
DrugBank: Arbutin (DB11217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta1-adrenoceptor selective blocker (metoprolol)
Study: 20124
Drug: Non-selective blockers
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective blockers (e.g., propranolol)
Study: 31308592
Drug: Traditional BPB
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Study: 31308592
Drug: Perpendicular BPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perpendicular BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Study: 31308592
Drug: Axillary BPB
Normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axillary BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Study: 25173085
Drug: IMRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT with dose constraints on the brachial plexus (BP) (maximum dose limit of ≤66 Gy)
Study: 25173085
Drug: IMRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT with dose constraints on the BP
Study: 11782868
Drug: Regular cow
Normalized name: Cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular cow milk protein-based formula with added cholesterol (RF+cholesterol) 3.44 mmol cholesterol/L (133 mg cholesterol/L)
Study: 2748223
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (salbutamol)
Study: 29292066
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of 5.0 ppm F milk once per day
Study: 29292066
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 5.0 ppm F twice per day
Study: 29292066
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of 5.0 ppm F once every other day
Study: 29292066
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (once per day, twice per day, once every other day)
Study: 26864002
Drug: Intrathecal anaesthesia
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal anaesthesia with 40 mg intrathecal hyperbaric prilocaine
Study: 26864002
Drug: Peripheral nerve
Normalized name: Peripheral nerve antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral nerve blockade with 25 ml mepivacaine 2%
Study: 20169950
Drug: Rocuronium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.4 mg x kg(‐1)
Study: 20169950
Drug: Rocuronium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.5 mg x kg(‐1)
Study: 20169950
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg x kg(‐1)
Study: 15694877
Drug: Electronic daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic daily diary assessment of pain-related variables
Study: 1876742
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine with 0.05 mg of fentanyl
Study: 21532072
Drug: Systematic implementation
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic implementation of behavioral interventions including trauma-informed care training, changes to unit rules and language, changes to the physical characteristics of the therapeutic environment, and involvement of patients in treatment planning.
Study: 18971549
Drug: Losartan (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (12.5 mg/d)
Study: 18971549
Drug: Control (antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antiplatelet agents)
Study: 16155076
Drug: rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 8 mg daily for 12 weeks
Study: 16155076
Drug: rosiglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 2 mg daily for 12 weeks
Study: 16155076
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg daily for 12 weeks
Study: 10849267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Interferon-a2a (IFN) with oral ganciclovir
Study: 9089855
Drug: Clonidine 5
Normalized name: apraclonidine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 5 micrograms/mL with lidocaine 1.5%
Study: 9089855
Drug: Epinephrine 5
Normalized name: epinephrine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 5 micrograms/mL with lidocaine 1.5%
Study: 30600521
Drug: Thula Baba
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thula Baba Box (TBB) and monthly Community Health Worker (CHW) visits
Study: 29970875
Drug: Breviscapine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breviscapine (40 mg)
Study: 21950300
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (MTX) 2.5 mg daily for 4 weeks
Study: 21950300
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (MTX) weekly (not specified dosage)
Study: 21950300
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (MTX) daily
Study: 21950300
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (MTX) weekly
Study: 18449064
Drug: 0.25% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% chlorhexidine solution
Study: 18449064
Drug: 0.50% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50% chlorhexidine solution
Study: 18449064
Drug: 1.00% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.00% chlorhexidine solution
Study: 16540246
Drug: Adequate antipsychotic
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate antipsychotic treatment
Study: 12488289
Drug: Single 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 6 mg subcutaneous injection of pegfilgrastim
Study: 12488289
Drug: Daily 5
Normalized name: Walgreens Gold Seal One Daily 50 Plus Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 5 mg/kg subcutaneous injections of filgrastim
Study: 11403727
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 100 mg/day
Study: 9517526
Drug: rice ORS
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rice ORS containing 50 g/l rice and 70 mmol/l Na+
Study: 9517526
Drug: ORS containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS containing 70 mmol/l Na+ and 16.2 g/l glucose
Study: 9517526
Drug: rice ORS
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rice ORS containing 50 g/l rice and 90 mmol/l Na+
Study: 3140683
Drug: Metrifonate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (10 mg/kg x 3 doses)
Study: 3140683
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg x 1 dose)
Study: 23883816
Drug: Synthetic bioabsorbable
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic bioabsorbable antibiotic-soaked nasal sponge in the middle meatus (MM)
Study: 23883816
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative oral antibiotic prophylaxis (1 week) and saline-soaked bioabsorbable MM sponge
Study: 21039936
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B at 3 mg kg(‐1) QD for 14 days, followed by 3 mg kg(‐1) QD
Study: 21039936
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B at 10 mg kg(‐1) QD for 14 days, followed by 3 mg kg(‐1) QD
Study: 7837745
Drug: Control glucose-nitrate
Normalized name: GLUCOSE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control glucose-nitrate solution
Study: 27901334
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (MC and ALA)
Study: 24708696
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) therapy
Study: 18661082
Drug: 3% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% mepivacaine hydrochloride injection
Study: 12598719
Drug: Bifidobacterium-administered group
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium-administered group (oral administration of lyophilized bifidobacteria, Bifidobacterium breve M‐16V strain)
Study: 12598719
Drug: Bifidobacterium-administered group
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium-administered group
Study: 8693541
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg OKT3
Study: 1657197
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of alcoholics and drug addicts
Study: 1657197
Drug: Separate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate treatment of alcoholics and drug addicts
Study: 31841507
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 IU loading dose followed by 20,000 IU/week)
Study: 24786928
Drug: Open-label MEP
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label MEP treatment
Study: 24786928
Drug: MEP (more
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEP (more aggressive therapy)
Study: 22424948
Drug: Cycled parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycled parenteral nutrition (n = 34)
Study: 22424948
Drug: Continuous parenteral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous parenteral nutrition (n = 36)
Study: 21061393
Drug: 0.1% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% capsaicin cream
Study: 12078912
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of chemotherapy (CT) with (sub)total nodal irradiation (RT) as consolidation treatment.
Study: 12078912
Drug: Early intensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensive therapy including intensified cytoreductive CT and high-dose CT with autologous stem-cell transplantation.
Study: 12078912
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of eight doxorubicin-bleomycin-vinblastine-dacarbazine.
Study: 31324862
Drug: Neostigmine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.05 mg/kg
Study: 10422928
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg
Study: 10422928
Drug: Neostigmine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.05 mg/kg after 2 min
Study: 10422928
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg after 2 min
Study: 10422928
Drug: Neostigmine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.05 mg/kg after 5 min
Study: 10422928
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg after 5 min
Study: 479384
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dezocine
Study: 29113731
Drug: Oral fexinidazole
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fexinidazole (1800 mg on days 1-4, 1200 mg on days 5-10)
Study: 29113731
Drug: Nifurtimox eflornithine
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox eflornithine combination therapy (15 mg/kg per day for 10 days, 400 mg/kg per day for 7 days)
Study: 29113731
Drug: Nifurtimox eflornithine
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox eflornithine combination therapy
Study: 23085245
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg daily)
Study: 18977983
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with desmopressin and extended-release anticholinergic medication
Study: 8632337
Drug: Pindolol administration
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol administration (10 mg twice daily) with NH4Cl (1.5 g every 6 hr)
Study: 8632337
Drug: Control phase:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control phase: Pindolol administration (10 mg twice daily) without NH4Cl
Study: 17137759
Drug: Typical antipsychotics
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotics (oral and depot)
Study: 2368243
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (absolute controls)
Study: 519269
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with medication monitor
Study: 29173199
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (3.7 g daily)
Study: 26209000
Drug: LCZ696 (dual‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (dual‐acting angiotensin receptor blocker and neprilysin inhibitor)
Study: 12074617
Drug: Steroid (Depo‐Medrone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (Depo‐Medrone) injection preoperatively
Study: 8175411
Drug: Radiotherapy for
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy for left sided breast cancer (either tangential field 60Co or electron-therapy)
Study: 6439699
Drug: Photon radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Photon radiation therapy
Study: 30482511
Drug: First trimester
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First trimester tear osmolarity measurement (304.9 ± 8.0 mOsm/L)
Study: 30482511
Drug: Last trimester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Last trimester tear osmolarity measurement (300.2 ± 7.1 mOsm/L)
Study: 28112433
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (medication management)
Study: 25847775
Drug: Huanshuai Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huanshuai Recipe Oral Liquid (HSR), 20 mL, 3 times a day for 6 months
Study: 21392111
Drug: Talaporfin sodium
Normalized name: Talaporfin
DrugBank: Talaporfin (DB11812)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Talaporfin sodium (0.25-1.0 mg/kg)
Study: 18490847
Drug: Pre-germinated brown
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-germinated brown rice (PGBR) diet (3 packs of cooked PGBR, 180 g/pack daily for 6 weeks)
Study: 18490847
Drug: White rice
Normalized name: White Rice
Approvals — FDA: no, EMA: no, PMDA: no
Description: White rice (WR) diet (3 packs of cooked WR, 180 g/pack daily for 6 weeks)
Study: 11506111
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg morphine infiltrated into the harvest site
Study: 11506111
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intramuscular morphine
Study: 8321112
Drug: L-carnitine (CARN)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (CARN) 3 g.d-1 for 7 d
Study: 8321112
Drug: L-carnitine (CARN)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (CARN)
Study: 3790647
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg Pindolol
Study: 3790647
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg Cloxazolam
Study: 3790647
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg Pindolol + 1.5 mg Cloxazolam
Study: 11573527
Drug: Phenylephrine 4
Normalized name: GFN 600/Phenylephrine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 4 mg i.m.
Study: 11573527
Drug: Phenylephrine 2
Normalized name: phenylephrine 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 2 mg i.m.
Study: 11573527
Drug: Ephedrine 45
Normalized name: pseudoephedrine 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 45 mg i.m.
Study: 29298938
Drug: Facial photos
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facial photos taken 2 h after injection with 2.0 ng kg‐1 lipopolysaccharide (bacterial stimulus)
Study: 29298938
Drug: Facial photos
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facial photos taken 2 h after injection with placebo
Study: 27354761
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate intranasal steroid
Study: 27354761
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate intranasal steroid
Study: 19785605
Drug: Topical miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical miltefosine and clobetasol
Study: 19785605
Drug: Topical miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical miltefosine
Study: 17431777
Drug: Adefovir 10
Normalized name: adefovir 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 10 mg/day (Group 1)
Study: 17431777
Drug: Adefovir 10
Normalized name: adefovir 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 10 mg/day and lamivudine 100 mg once daily (Group 2)
Study: 16280250
Drug: Levetiracetam (1,000-4,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (1,000-4,000 mg/day)
Study: 16280250
Drug: Levetiracetam monotherapy
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam monotherapy
Study: 15790985
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 microg twice daily
Study: 9949318
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 1000 microg twice daily
Study: 2262582
Drug: Triclosan containing
Normalized name: Triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclosan containing oral hygiene products
Study: 2262582
Drug: Stannous fluoride
Normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous fluoride containing oral hygiene products
Study: 31192643
Drug: Parents who
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents who received additional guidance to focus on teaching numbers during tablet play.
Study: 31192643
Drug: Parents who
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents who did not receive additional guidance to focus on teaching numbers during tablet play.